DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Targeting Androgen Receptor by Lysosomal Degradation in Prostate Cancer
Final rept. 1 Sep 2013-31 Aug 2015
TEXAS UNIV HEALTH SCIENCE CENTER AT SAN ANTONIO
Pagination or Media Count:
Androgen receptor AR plays a critical role in the progression of prostate cancer. This project is directed towards testing the feasibility of targeting AR for lysosomal degradation. We have demonstrated that AR can indeed be targeted for degradation by stimulating the TFEB-lysosome degradation pathway either by increasing the TFEB levels or by activating TFEB using mTORC1 kinase inhibitor, torin 1. Additionally, we determined that the same approach can be used to target the EWS-Fli-1 oncoprotein for degradation.
APPROVED FOR PUBLIC RELEASE